This trial will study whether a drug called SGN-B6A is safe for people with solid tumors, what its side effects are, and whether it works to treat cancer.
9 Primary · 12 Secondary · Reporting Duration: Up to approximately 3 years
355 Total Participants · 1 Treatment Group
Primary Treatment: SGN-B6A · No Placebo Group · Phase 1
Age 18+ · All Participants · 10 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
|MD Anderson Cancer Center / University of Texas||100.0%|